167 related articles for article (PubMed ID: 33707468)
1. Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope.
Makabe K; Yokoyama T; Uehara S; Uchikubo-Kamo T; Shirouzu M; Kimura K; Tsumoto K; Asano R; Tanaka Y; Kumagai I
Sci Rep; 2021 Mar; 11(1):5790. PubMed ID: 33707468
[TBL] [Abstract][Full Text] [Related]
2. Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and α5-integrin.
Wilken JA; Baron AT; Foty RA; McCormick DJ; Maihle NJ
Biochemistry; 2011 May; 50(20):4309-21. PubMed ID: 21491912
[TBL] [Abstract][Full Text] [Related]
3. Shedding of soluble epidermal growth factor receptor (sEGFR) is mediated by a metalloprotease/fibronectin/integrin axis and inhibited by cetuximab.
Wilken JA; Perez-Torres M; Nieves-Alicea R; Cora EM; Christensen TA; Baron AT; Maihle NJ
Biochemistry; 2013 Jul; 52(26):4531-40. PubMed ID: 23731208
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.
Li S; Schmitz KR; Jeffrey PD; Wiltzius JJ; Kussie P; Ferguson KM
Cancer Cell; 2005 Apr; 7(4):301-11. PubMed ID: 15837620
[TBL] [Abstract][Full Text] [Related]
5. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.
Voigt M; Braig F; Göthel M; Schulte A; Lamszus K; Bokemeyer C; Binder M
Neoplasia; 2012 Nov; 14(11):1023-31. PubMed ID: 23226096
[TBL] [Abstract][Full Text] [Related]
6. Real-time measurements of kinetics of EGF binding to soluble EGF receptor monomers and dimers support the dimerization model for receptor activation.
Zhou M; Felder S; Rubinstein M; Hurwitz DR; Ullrich A; Lax I; Schlessinger J
Biochemistry; 1993 Aug; 32(32):8193-8. PubMed ID: 8347619
[TBL] [Abstract][Full Text] [Related]
7. Stoichiometry, kinetic and binding analysis of the interaction between epidermal growth factor (EGF) and the extracellular domain of the EGF receptor.
Domagala T; Konstantopoulos N; Smyth F; Jorissen RN; Fabri L; Geleick D; Lax I; Schlessinger J; Sawyer W; Howlett GJ; Burgess AW; Nice EC
Growth Factors; 2000; 18(1):11-29. PubMed ID: 10831070
[TBL] [Abstract][Full Text] [Related]
8. Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping but distinct from the EGF-binding epitope.
Santra M; Reed CC; Iozzo RV
J Biol Chem; 2002 Sep; 277(38):35671-81. PubMed ID: 12105206
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.
Li S; Kussie P; Ferguson KM
Structure; 2008 Feb; 16(2):216-27. PubMed ID: 18275813
[TBL] [Abstract][Full Text] [Related]
10. Ligand-binding enhances the affinity of dimerization of the extracellular domain of the epidermal growth factor receptor.
Odaka M; Kohda D; Lax I; Schlessinger J; Inagaki F
J Biochem; 1997 Jul; 122(1):116-21. PubMed ID: 9276679
[TBL] [Abstract][Full Text] [Related]
11. Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.
Tintelnot J; Baum N; Schultheiß C; Braig F; Trentmann M; Finter J; Fumey W; Bannas P; Fehse B; Riecken K; Schuetze K; Bokemeyer C; Rösner T; Valerius T; Peipp M; Koch-Nolte F; Binder M
Mol Cancer Ther; 2019 Apr; 18(4):823-833. PubMed ID: 30824613
[TBL] [Abstract][Full Text] [Related]
12. Surfactant protein A down-regulates epidermal growth factor receptor by mechanisms different from those of surfactant protein D.
Hasegawa Y; Takahashi M; Ariki S; Saito A; Uehara Y; Takamiya R; Kuronuma K; Chiba H; Sakuma Y; Takahashi H; Kuroki Y
J Biol Chem; 2017 Nov; 292(45):18565-18576. PubMed ID: 28972165
[TBL] [Abstract][Full Text] [Related]
13. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains.
Schmitz KR; Bagchi A; Roovers RC; van Bergen en Henegouwen PM; Ferguson KM
Structure; 2013 Jul; 21(7):1214-24. PubMed ID: 23791944
[TBL] [Abstract][Full Text] [Related]
14. Surfactant protein D suppresses lung cancer progression by downregulation of epidermal growth factor signaling.
Hasegawa Y; Takahashi M; Ariki S; Asakawa D; Tajiri M; Wada Y; Yamaguchi Y; Nishitani C; Takamiya R; Saito A; Uehara Y; Hashimoto J; Kurimura Y; Takahashi H; Kuroki Y
Oncogene; 2015 Feb; 34(7):838-45. PubMed ID: 24608429
[TBL] [Abstract][Full Text] [Related]
15. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
[TBL] [Abstract][Full Text] [Related]
16. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
Schmiedel J; Blaukat A; Li S; Knöchel T; Ferguson KM
Cancer Cell; 2008 Apr; 13(4):365-73. PubMed ID: 18394559
[TBL] [Abstract][Full Text] [Related]
17. Polymorphism of the epidermal growth factor receptor extracellular ligand binding domain: the dimer interface depends on domain stabilization.
Zhang Z; Wriggers W
Biochemistry; 2011 Mar; 50(12):2144-56. PubMed ID: 21275429
[TBL] [Abstract][Full Text] [Related]
18. Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers.
Boje AS; Pekar L; Koep K; Lipinski B; Rabinovich B; Evers A; Gehlert CL; Krohn S; Xiao Y; Krah S; Zaynagetdinov R; Toleikis L; Poetzsch S; Peipp M; Zielonka S; Klausz K
MAbs; 2024; 16(1):2315640. PubMed ID: 38372053
[TBL] [Abstract][Full Text] [Related]
19. GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands.
Lim Y; Yoo J; Kim MS; Hur M; Lee EH; Hur HS; Lee JC; Lee SN; Park TW; Lee K; Chang KH; Kim K; Kang Y; Hong KW; Kim SH; Kim YG; Yoon Y; Nam DH; Yang H; Kim DG; Cho HS; Won J
Mol Cancer Ther; 2016 Feb; 15(2):251-63. PubMed ID: 26586721
[TBL] [Abstract][Full Text] [Related]
20. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425.
Kamat V; Donaldson JM; Kari C; Quadros MR; Lelkes PI; Chaiken I; Cocklin S; Williams JC; Papazoglou E; Rodeck U
Cancer Biol Ther; 2008 May; 7(5):726-33. PubMed ID: 18424917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
